PROK2 and myeloid sarcoma: Furthermore, serum prokineticin-2 levels were significantly elevated in participants with increased numbers of MS components (5.17 ± 2.29 vs 5.94 ± 2.47 vs 7.13 ± 3.33 vs 8.32 ± 2.81 vs 9.82 ± 4.37 ng/ml, P for trend <0.001, Fig. 1).